



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 68332

Title: Itraconazole therapy for infant hemangioma: case report

Reviewer's code: 05906528

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor, Staff Physician

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-05-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-19 23:07

Reviewer performed review: 2021-05-22 23:26

Review time: 3 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

These 2 case reports have clearly shown satisfactory outcomes of Itraconazole treatment in infantile hemangioma. I agree with authors that large scale studies and randomized clinical trials with comparison to propranolol are required to confirm efficacy, dosing, and safety profile of Itraconazole in treatment of infantile hemangioma. Long term follow up of these patient is required to see the long term side effects of Itraconazole in these patients.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 68332

Title: Itraconazole therapy for infant hemangioma: case report

Reviewer's code: 01557050

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2021-05-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-20 00:25

Reviewer performed review: 2021-05-23 08:49

Review time: 3 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

1) General comments Dr. Liu and Dr. Li, et al. reported 'Itraconazole therapy for infant hemangioma: case report'. The article is informative and well presentation. The reviewer has some comments. 1. The authors gave two babies oral itraconazole at the dose of 5 mg/kg/d according to the Dr. Ran's report. Then, the authors should explain the prospect of administration period of itraconazole. And the author also needs to explain the skin findings of terminating itraconazole. Because in Case 1, the authors described in page 4 line 98 "On day 80, the size and color of lesions were reduced further (Fig. 1), therefore itraconazole administration was halted.", and in Case 2, in page 6 line 128, "After day 90, the baby's parents decided by themselves to stop the medication and no longer visit the hospital." The reviewer thinks the authors had no plan to administer this drug. 2. In Figure 1, this case 1 had hemangiomas at on the right hand. However, findings at 43 days and at 124 days after itraconazole treatment showed at the left hand. Please confirm these pictures. 3. In CONCLUSION, the authors should describe more briefly. Therefore, the authors can move some sentences from CONCLUSION to DISCUSSION. 4. The authors should explain the reason how oral itraconazole administration was given first in DISCUSSION.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 68332

Title: Itraconazole therapy for infant hemangioma: case report

Reviewer's code: 05908908

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor, Senior Lecturer, Surgeon

Reviewer's Country/Territory: Indonesia

Author's Country/Territory: China

Manuscript submission date: 2021-05-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-23 22:56

Reviewer performed review: 2021-05-24 12:28

Review time: 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

1. Very interesting article discussing itraconazole as an alternative therapy in infantile hemangioma. Cases and discussions are well written, references included are up to date.
2. In the discussion line 160, Bessar et al compared IHs treatment between propranolol and itraconazole, please explain why itraconazole is better and safer than propranolol? If there are other studies compare the comparison of propranolol and itraconazole, please add them in the discussion to increase clinician understanding of alternative therapies for IHs.
3. Make conclusions concise and clear. The method of administration of itraconazole can be moved to the Discussion subheading.
4. Does itraconazole become the standard therapy for IHs in your hospital? If not, please attach the ethical clearance of the study and/or the informed consent of therapy in author patients.